全球医药CDMO市场规模、份额、趋势和成长分析报告（2026-2034年）

预计医药CDMO市场将从2025年的1,821.5亿美元成长到2034年的3,474.8亿美元，2026年至2034年的复合年增长率为7.44%。

随着製药公司越来越多地将药物研发和生产流程外包，全球合约研发生产机构（CDMO）市场正经历强劲成长。 CDMO提供药物製剂、临床试验用药生产和大规模生产等专业服务，使製药公司能够专注于研发和商业化。

市场的主要驱动因素之一是药物研发日益复杂以及生产设施建设成本不断攀升。製药和生物技术公司依赖合约研发生产机构（CDMO）来降低营运成本并缩短产品研发週期。此外，生物製药和个人化医疗的成长也推动了对专业化生产能力的需求。

随着全球药品研发管线的不断扩展，药品合约研发生产力机构（CDMO）市场也预计将随之成长。生物技术研发投入的增加以及创新治疗方法的开发将进一步推动对外包服务的需求。凭藉製造技术的进步和监管方面的专业知识，CDMO将在未来的药品生产中发挥至关重要的作用。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球医药CDMO市场：依产品划分

• 市场分析、洞察与预测
• API
• 製药

第五章 全球医药CDMO市场：依工作流程划分

• 市场分析、洞察与预测
• 临床阶段
• 商业的

第六章 全球医药CDMO市场：依应用领域划分

• 市场分析、洞察与预测
• 肿瘤学
• 低分子化合物
• 生物製剂
• 感染疾病
• 神经系统疾病
• 心血管疾病
• 代谢性疾病
• 自体免疫疾病
• 呼吸系统疾病
• 眼科
• 消化系统疾病
• 荷尔蒙失调
• 血液疾病
• 其他的

第七章 全球医药CDMO市场：依最终用途划分

• 市场分析、洞察与预测
• 小规模製药公司
• 中型製药公司
• 大型製药企业

第八章 全球医药CDMO市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Lonza
  • Thermo Fisher Scientific Inc
  • Recipharm AB
  • Laboratory Corporation Of America Holdings（LabCorp）
  • Catalent Inc
  • WuXi AppTec Inc
  • Samsung Biologics
  • Piramal Pharma Solutions
  • Siegfried Holding AG
  • CordenPharma International
  • Cambrex Corporation
  • Bushu Pharmaceuticals Ltd
  • Nipro Corporation

The Pharmaceutical CDMO Market size is expected to reach USD 347.48 Billion in 2034 from USD 182.15 Billion (2025) growing at a CAGR of 7.44% during 2026-2034.

The Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market is experiencing strong growth as pharmaceutical companies increasingly outsource drug development and manufacturing processes. CDMOs provide specialized services such as drug formulation, clinical trial manufacturing, and large-scale production, allowing pharmaceutical companies to focus on research and commercialization.

One of the primary drivers of the market is the rising complexity of drug development and the increasing cost of establishing manufacturing facilities. Pharmaceutical and biotechnology companies rely on CDMOs to reduce operational expenses and accelerate product development timelines. Additionally, the growth of biologics and personalized medicines has increased demand for specialized manufacturing capabilities.

Looking ahead, the pharmaceutical CDMO market is expected to expand as the global pharmaceutical pipeline continues to grow. Increasing investment in biotechnology research and the development of innovative therapies will further drive demand for outsourcing services. With advancements in manufacturing technologies and regulatory compliance expertise, CDMOs will play a crucial role in the future of pharmaceutical production.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• API
• Drug Product

By Workflow

• Clinical
• Commercial

By Application

• Oncology
• Small Molecules
• Biologics
• Infectious Diseases
• Neurological Disorders
• Cardiovascular Disease
• Metabolic Disorders
• Autoimmune Diseases
• Respiratory Diseases
• Ophthalmology
• Gastrointestinal Disorders
• Hormonal Disorders
• Hematological Disorders
• Others

By End-use

• Small Pharmaceutical Companies
• Medium Pharmaceutical Companies
• Large Pharmaceutical Companies

COMPANIES PROFILED

• Lonza, Thermo Fisher Scientific Inc, Recipharm AB, Laboratory Corporation of America Holdings LabCorp, Catalent Inc, WuXi AppTec Inc, Samsung Biologics, Piramal Pharma Solutions, Siegfried Holding AG, CordenPharma International, Cambrex Corporation, Bushu Pharmaceuticals Ltd, Nipro Corporation
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PHARMACEUTICAL CDMO MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. API Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Drug Product Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PHARMACEUTICAL CDMO MARKET: BY WORKFLOW 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Workflow
• 5.2. Clinical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Commercial Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PHARMACEUTICAL CDMO MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Small Molecules Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Biologics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Neurological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Cardiovascular Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.8. Metabolic Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.9. Autoimmune Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.10. Respiratory Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.11. Ophthalmology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.12. Gastrointestinal Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.13. Hormonal Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.14. Hematological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.15. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PHARMACEUTICAL CDMO MARKET: BY END-USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End-use
• 7.2. Small Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Medium Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Large Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL PHARMACEUTICAL CDMO MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product
  • 8.2.2 By Workflow
  • 8.2.3 By Application
  • 8.2.4 By End-use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product
  • 8.3.2 By Workflow
  • 8.3.3 By Application
  • 8.3.4 By End-use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product
  • 8.4.2 By Workflow
  • 8.4.3 By Application
  • 8.4.4 By End-use
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product
  • 8.5.2 By Workflow
  • 8.5.3 By Application
  • 8.5.4 By End-use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product
  • 8.6.2 By Workflow
  • 8.6.3 By Application
  • 8.6.4 By End-use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL PHARMACEUTICAL CDMO INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Lonza
  • 10.2.2 Thermo Fisher Scientific Inc
  • 10.2.3 Recipharm AB
  • 10.2.4 Laboratory Corporation Of America Holdings (LabCorp)
  • 10.2.5 Catalent Inc
  • 10.2.6 WuXi AppTec Inc
  • 10.2.7 Samsung Biologics
  • 10.2.8 Piramal Pharma Solutions
  • 10.2.9 Siegfried Holding AG
  • 10.2.10 CordenPharma International
  • 10.2.11 Cambrex Corporation
  • 10.2.12 Bushu Pharmaceuticals Ltd
  • 10.2.13 Nipro Corporation